Recursion Pharmaceuticals (RXRX) Invested Capital (2020 - 2026)

Recursion Pharmaceuticals has reported Invested Capital for 7 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 9.71% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 9.71% YoY), and the FY2025 full-year result was $1.1 billion, up 9.27% from the prior year.
• Invested Capital for Q1 2026 stood at $1.0 billion, down from $1.1 billion in the prior quarter.
• The five-year high for Invested Capital was $1.1 billion in Q4 2025, with the low at $388.0 million in Q3 2022.
• Historically, Invested Capital has averaged $663.3 million across 5 years, with a median of $493.6 million in 2022.
• The largest YoY upside for Invested Capital was 311.8% in 2022 against a maximum downside of 35.22% in 2022.
• Recursion Pharmaceuticals' Invested Capital stood at $485.8 million in 2022, then declined by 4.6% to $463.5 million in 2023, then soared by 125.08% to $1.0 billion in 2024, then advanced by 9.27% to $1.1 billion in 2025, then slipped by 9.29% to $1.0 billion in 2026.
• The last three Invested Capital figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.